Inhibition of Cyclin-Dependent Kinases - A Review of the Recent Patent Literature
The cyclin dependent kinases, Cdks, are potential targets for new anticancer therapy. Dysregulation of the cell cycle is common during tumorigenesis, and inhibition of certain Cdks has been shown to inhibit tumor cell growth, induce apoptosis and cause tumor regressions in animal models. This review discusses the rationale for inhibiting Cdks as an approach to cancer therapy and the status of Cdk inhibitors in clinical trials. Compounds resulting from a patent literature search from 2003 to July, 2005 are discussed.
No Supplementary Data
No Article Media
Document Type: Research Article
Affiliations: Schering-Plough Research Institute, Department of Tumor Biology, Departmant of Chemical Research, 2015 Galloping Hill Road, Kenilworth, NJ 07033-1300, USA.
Publication date: November 1, 2006
More about this publication?
- Recent Patents on Anti-Cancer Drug Discovery publishes review articles on recent patents in the field of anti-cancer drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-cancer drug design and discovery.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites